IP
AKBA icon

Isthmus Partners’s Akebia Therapeutics AKBA Stock Holding History

Isthmus Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-825
Closed -$7K – 140
2018
Q3 		$7K Buy
825
+414
+101% +$3.7K ﹤0.01% 252
2018
Q2 		$4K Hold
411
– – ﹤0.01% 254
2018
Q1 		$4K Hold
411
– – ﹤0.01% 252
2017
Q4 		$6K Hold
411
– – ﹤0.01% 254
2017
Q3 		$8K Buy
+411
New +$6.32K ﹤0.01% 248

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Isthmus Partners's AKBA Position: Q4 2018 in Review

Isthmus Partners sold out of Akebia Therapeutics (AKBA) in Q4 2018, closing a stake of 825 shares — an estimated $7K sold.

Isthmus Partners first reported a position in AKBA in Q3 2017 and held it in 5 quarters. The position peaked at $8K in Q3 2017. 166 funds tracked by Wall St. Rank hold AKBA as of Q4 2018.

  • Isthmus Partners reported no remaining Akebia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Isthmus Partners sold 825 Akebia Therapeutics shares in Q4 2018, an estimated $7K.
  • Isthmus Partners first reported a position in Akebia Therapeutics in Q3 2017 and held it in 5 quarters.
  • Isthmus Partners's Akebia Therapeutics position peaked at $8K in Q3 2017.
  • 166 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2018.

Based on Isthmus Partners's 13F filing for Q4 2018, filed 4 Feb 2019.